Table 1 Evolution of ALFTs, stages of stopping immunosuppressive drugs, and in-hospital outcomes
Laboratory tests (2018) | Jan 23 | Mar 07 | April 24 | Jun 13 | Sept 11 | Oct 09 | Oct 22 | Nov 16 | Dec 02 | Dec 13 |
|---|---|---|---|---|---|---|---|---|---|---|
ALT (NR 0–55 U/L) | 43 | 14 | 10 | 12 | 11 | 13 | 11 | 200 (H) | 25 | 11 |
AST (NR 5–34 U/L) | 15 | 12 | 14 | 15 | 14 | 18 | 17 | 91 | 24 | 18 |
ALP (NR 42–98 U/L) | 117 | 57 | 62 | 71 | 89 | 82 | 69 | 801 | 90 | 86 |
γ-GT (NR 9–36 U/L) | 134 | 23 | 12 | 28 | 11 | 11 | 10 | 305 | 30 | 11 |
Total bilirubin (NR 0–20 μmol/L) | 10 | 9 | 5 | 7 | 5 | 5 | 3 | 16 | 18 | 7 |
Leukocytes (NR 4000–10,000 cells/mm3) | 6900 | 5400 | 2300 (A) | 2200 (B) | 1800 | 1800 | 1700 | 4970 | 6.2 | 5.70 |
PMN (NR 1300–7500 cells/mm3) | - | - | 287 | 440 | 455 | 369 | 643 | 3280 | 4.02 | 3.90 |
Creatinine level (NR 49–90 μmol/L) | 91 | 115 | 133 | 160 (C) | 170 (D) | 178 (F) | 166 | 171 | 145 | 138 |
Hemoglobin (NR12–16 g/dL) | 11.4 | 11 | 10 | 10 | 9 | 9.4 | 8.6 | 7.8 | 12.5 | 10 |
Residual tacrolimus level (objective 6–10 ng/mL) | 9.2 | 8.6 | 6 | 7.7 | 4.6 | 3.6 | - | - | 9.3 | 8.9 |
Residual everolimus level (objective 5–10 ng/mL) | - | - | - | - | (E) | 6.4 (G) | 5.7 | 4.5 | 5 | 5.7 |